title: STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases.
abstract: Lipoprotein associated phospholipase A2 (Lp-PLA2) - an enzyme with several pro-inflammatory properties - has been hypothesized to be involved in the pathogenesis of atherosclerosis and plaque vulnerability. Lp-PLA2 activity has been demonstrated to be an independent predictor of coronary heart disease (CHD) and ischemic stroke. However, it has been recently reported that carriers of loss of function variants in PLA2G7 gene (encoding Lp-PLA2) had no lower CHD risk than non-carriers. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY), and the Stabilization of Plaque Using Darapladib - Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) studies are two phase III, randomized, placebo-controlled, clinical trials that were conducted to evaluate the clinical efficacy and safety of the Lp-PLA2 inhibitor (darapladib), against a background of optimal medical therapy, in patients with stable CHD and acute coronary syndrome, respectively. In both studies, darapladib failed to reduce the risk of major coronary events as compared to placebo. In addition, darapladib was associated with significantly higher rates of drug discontinuation, and adverse side effects such as diahrrea and malodorous feces, urine, and skin, as compared to placebo. These data suggest that Lp-PLA2 may be a biomarker of vascular inflammation rather than a causal pathway of cardiovascular (CV) diseases. It also challenges the notion that inhibition of Lp-PLA2 is a worthwhile approach in patients with CHD. Alternate therapies that target inflammation are awaited to reduce residual risk in patients with CV diseases.
authors.forename: Mohamed
authors.initials: M
authors.lastname: Hassan
references.citation: J Clin Invest. 1995 Feb;95(2):774-82
references.pmid: 7860760
references.citation: N Engl J Med. 2015 Jan 15;372(3):295-6
references.pmid: 25587968
references.citation: JAMA. 2014 Sep 10;312(10):1006-15
references.pmid: 25173516
references.citation: Eur Heart J. 2009 Dec;30(23):2829-31
references.pmid: 19720637
references.citation: Circulation. 2005 Feb 8;111(5):570-5
references.pmid: 15699277
references.citation: Arterioscler Thromb Vasc Biol. 2005 May;25(5):923-31
references.pmid: 15731492
references.citation: Circulation. 2004 Feb 24;109 (7):837-42
references.pmid: 14757686
references.citation: Glob Cardiol Sci Pract. 2014 Dec 31;2014(4):360-6
references.pmid: 25780789
references.citation: Glob Cardiol Sci Pract. 2014 Dec 31;2014(4):355-9
references.pmid: 25780788
references.citation: Glob Cardiol Sci Pract. 2013 Dec 30;2013(4):343-7
references.pmid: 24749106
references.citation: Circulation. 2008 Sep 9;118(11):1172-82
references.pmid: 18765397
references.citation: Circulation. 2010 Jun 1;121(21):2284-93
references.pmid: 20479152
references.citation: Lancet. 2010 May 1;375(9725):1536-44
references.pmid: 20435228
references.citation: Pharmacogenomics J. 2012 Oct;12(5):425-31
references.pmid: 21606947
references.citation: Biochim Biophys Acta. 2006 Nov;1761(11):1351-8
references.pmid: 16807087
references.citation: N Engl J Med. 2014 May 1;370(18):1702-11
references.pmid: 24678955
references.citation: Clin Chem. 2012 May;58(5):877-86
references.pmid: 22419750